Autor:	D. Mahadevan, J.M. Pagel, H. Quach, A. Mohrbacher, W. Rybka, P. Walker, J. Gwo, Francisco J. Hernandez-Ilizaliturri, Gareth P. Gregory, Stephen Opat, D. Wang, Julie E. Chang, Nina D. Wagner-Johnston, H. Ma, M. Farooqui, Andreas K. Klein, C. Escobar, Jake Shortt
Rok vydání:	2019
Předmět:	Antitumor activity chemistry.chemical_compound chemistry business.industry Cancer research Medicine In patient Hematology Pembrolizumab Dinaciclib business medicine.disease Diffuse large B-cell lymphoma
Zdroj:	HemaSphere. 3:487
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000562592.55862.c5
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::47607f3e857734670b78cdd14094ce42 https://doi.org/10.1097/01.hs9.0000562592.55862.c5 Zobrazit plný text záznamu Plný text